About this trial
Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.
Eligibility criteria
Qualifiers
Willing and able to provide written informed consent.
Systemically healthy (no history of diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions that could affect periodontal status).
Have a minimum of 20 natural teeth (excluding third molars).
No antibiotic therapy or periodontal treatment in the last 6 months.
Disqualifiers
Fewer than 20 natural teeth (excluding third molars).
Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer).
Use of antibiotics or receiving periodontal treatment in the last 6 months.
Pregnancy or lactation.
Trial design
Treatments tested in this trial
- Non-surgical Periodontal Therapy (Scaling and Root Planing)
- Saliva Collection
Treatment groups
Sponsors and collaborators
Ömer Faruk Okumuş
Lead sponsor
Erzincan University
Sponsor institution